Panbela Therapeutics, Inc. ( (PBLA) ) has released its Q3 earnings. Here is a breakdown of the information Panbela Therapeutics, Inc. presented ...

It might be possible for people in the future to consume BHB-Phe to drive weight loss without restricting carbohydrates in ...

Our lead assets ivospemin, eflornithine, and Flynpovi target the polyamine pathway in ways that could complement ImmunityBio's natural killer cell and killer T cell activation technology. The ...

By combining Panbela's polyamine metabolic inhibitor platform ... I believe the combination of immunotherapy and metabolic pathway platforms could create powerful synergies in enhancing patient ...